-
1
-
-
0031963294
-
Cancer statistics, 1998
-
Landis SH, Murray T, Bolder S, et al.: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-31.
-
(1998)
CA Cancer J Clin
, vol.48
, pp. 6-31
-
-
Landis, S.H.1
Murray, T.2
Bolder, S.3
-
2
-
-
0030054309
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
-
Mcguire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
-
(1996)
N Engl J Med
, vol.334
, pp. 1-6
-
-
Mcguire, W.P.1
Hoskins, W.J.2
Brady, M.F.3
-
3
-
-
0000264166
-
Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment for advanced ovarian cancer: Mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and scottish intergroup trial
-
Stuart G, Bertelsen K, Magioni C, et al.: Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment for advanced ovarian cancer: Mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and Scottish Intergroup Trial [Abstract]. Proc Am Soc Clin Oncol 1998;17:361A.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Stuart, G.1
Bertelsen, K.2
Magioni, C.3
-
4
-
-
0024522049
-
Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design for phase II trials
-
Blackledge G, Lawton F, Redman C, et al.: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design for phase II trials. BMJ 1989;59:650-653.
-
(1989)
BMJ
, vol.59
, pp. 650-653
-
-
Blackledge, G.1
Lawton, F.2
Redman, C.3
-
5
-
-
0030915166
-
Treatment of recurrent ovarian cancer: Increasing options - "Recurrent results."
-
Ozols RF: Treatment of recurrent ovarian cancer: Increasing options - "recurrent results." J Clin Oncol 1997;15:2177-2180.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2177-2180
-
-
Ozols, R.F.1
-
6
-
-
0000626027
-
A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer
-
Armstrong D, Rowinsky E, Donehower R, et al.: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:275A.
-
(1995)
Proc Am Soc Clin Oncol
, vol.14
-
-
Armstrong, D.1
Rowinsky, E.2
Donehower, R.3
-
7
-
-
10544229791
-
Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of large European phase II study
-
Creemers GJ, Bolis G, Gore M, et al.: Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of large European phase II study. J Clin Oncol 1996;14:3056-3061.
-
(1996)
J Clin Oncol
, vol.14
, pp. 3056-3061
-
-
Creemers, G.J.1
Bolis, G.2
Gore, M.3
-
8
-
-
0000391321
-
Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International topotecan study group trial
-
Gordon A, Bookman M, Malmstrom H, et al.: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial [Abstract]. Proc Am Soc Clin Oncol 1996;15:282A.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
-
-
Gordon, A.1
Bookman, M.2
Malmstrom, H.3
-
9
-
-
9244247616
-
Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma
-
Kudelka AP, Tresukosol D, Edwards CL, et al.: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-1557.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1552-1557
-
-
Kudelka, A.P.1
Tresukosol, D.2
Edwards, C.L.3
-
10
-
-
0003241320
-
Final analysis of a phase III randomized study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian cancer (OC): International topotecan study group
-
Gordon A, Carmichael J, Malfetano J, et al.: Final analysis of a phase III randomized study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian cancer (OC): International Topotecan Study Group [Abstract]. Proc Am Soc Clin Oncol 1998;17:356A.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Gordon, A.1
Carmichael, J.2
Malfetano, J.3
-
11
-
-
0030900145
-
Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer
-
ten Bokkel Huinink W, Gore M, Carmichael J, et al.: Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2183-2193
-
-
Ten Bokkel Huinink, W.1
Gore, M.2
Carmichael, J.3
-
12
-
-
0031894188
-
Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A gynecologic oncology group study
-
Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1998;16:405-410.
-
(1998)
J Clin Oncol
, vol.16
, pp. 405-410
-
-
Rose, P.G.1
Blessing, J.A.2
Mayer, A.R.3
-
13
-
-
0030881725
-
Salvage weekly paclitaxel in recurrent ovarian cancer
-
Abu-Rustum NR, Aghajanian C, Barakat RR, et al.: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997;24(Suppl. 15):62-67.
-
(1997)
Semin Oncol
, vol.24
, Issue.SUPPL. 15
, pp. 62-67
-
-
Abu-Rustum, N.R.1
Aghajanian, C.2
Barakat, R.R.3
-
14
-
-
0002360126
-
Phase I study of weekly cisplatin (P) and weekly or 4 weekly Taxol (T): A highly active regimen in advanced epithelial ovarian cancer (OC)
-
van der Burg MEL, de Wit R, Stoter G, et al.: Phase I study of weekly cisplatin (P) and weekly or 4 weekly Taxol (T): a highly active regimen in advanced epithelial ovarian cancer (OC) [Abstract], Proc Am Soc Clin Oncol 1998;17:355A.
-
(1998)
Proc Am Soc Clin Oncol
, vol.17
-
-
Van Der Burg, M.E.L.1
De Wit, R.2
Stoter, G.3
-
15
-
-
0031055830
-
Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
-
Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-993.
-
(1997)
J Clin Oncol
, vol.15
, pp. 987-993
-
-
Muggia, F.M.1
Hainsworth, J.D.2
Jeffers, S.3
-
18
-
-
0001951950
-
Combination regimens with topotecan in animal tumor models
-
Johnson RK, McCabe FL, Yu Y: Combination regimens with topotecan in animal tumor models. Ann Oncol 1992;3:85-88.
-
(1992)
Ann Oncol
, vol.3
, pp. 85-88
-
-
Johnson, R.K.1
McCabe, F.L.2
Yu, Y.3
-
19
-
-
0031905299
-
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems
-
Romanelli S, Perego P, Pratesi G, et al.: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998;41:385-390.
-
(1998)
Cancer Chemother Pharmacol
, vol.41
, pp. 385-390
-
-
Romanelli, S.1
Perego, P.2
Pratesi, G.3
-
20
-
-
10544249871
-
Sequences of topotecan and cisplatin: A phase I, pharmacologic, and in vitro study to examine sequence dependence
-
Rowinsky EK, Kaufmann SH, Baker SD, et al.: Sequences of topotecan and cisplatin: A phase I, pharmacologic, and in vitro study to examine sequence dependence. J Clin Oncol 1996;14: 3074-3084.
-
(1996)
J Clin Oncol
, vol.14
, pp. 3074-3084
-
-
Rowinsky, E.K.1
Kaufmann, S.H.2
Baker, S.D.3
-
21
-
-
0027999967
-
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group B study
-
Miller AA, Hargis JB, Lilenbaum RC, et al.: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study. J Clin Oncol 1994;12: 2743-2750.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2743-2750
-
-
Miller, A.A.1
Hargis, J.B.2
Lilenbaum, R.C.3
Et, A.4
-
22
-
-
0024420685
-
Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as mechanism of cell killing by camptothecin
-
Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as mechanism of cell killing by camptothecin. Cancer Res 1989;49: 5077-5082.
-
(1989)
Cancer Res
, vol.49
, pp. 5077-5082
-
-
Hsiang, Y.H.1
Lihou, M.G.2
Liu, L.F.3
-
23
-
-
0029993118
-
Treatment related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel
-
Miller AA, Lilenbaum RC, Lynch TJ, et al.: Treatment related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel . J Clin Oncol 1996;14:1964-1965.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1964-1965
-
-
Miller, A.A.1
Lilenbaum, R.C.2
Lynch, T.J.3
-
24
-
-
0343976836
-
Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462)
-
Lilenbaum RC, Miller AA, Batist G, et al.: Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462) [Abstract]. Proc Am Soc Clin Oncol 1996;15:485A.
-
(1996)
Proc Am Soc Clin Oncol
, vol.15
-
-
Lilenbaum, R.C.1
Miller, A.A.2
Batist, G.3
|